Insider at

04

Insider transactions

05
0 buys (P) 3 sells (S) Net: $-13,171 + 9 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

9 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
March 16, 2026 TLSIW S 273 $4.12 $1,125 97,364 Direct -0.28% Disposed -79.4% (price as of 2026-10-02)
March 12, 2026 TLSIW S 1,772 $4.09 $7,247 97,637 Direct -1.78% Disposed -79.2% (price as of 2026-10-02)
March 11, 2026 TLSIW S 1,162 $4.13 $4,799 99,409 Direct -1.16% Disposed -79.4% (price as of 2026-10-02)
May 19, 2025 TLSIW S 4,764 $5.18 $24,678 52,764 Direct -8.28% Disposed -83.6% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Nov. 24, 2025 TLSIW Employee Stock Option (right to buy) Common Stock (100,000) $5.55 Nov. 23, 2025 100,000 Acquired
Jan. 27, 2025 TLSIW Employee Stock Option (right to buy) Common Stock (63,750) $5.30 Jan. 26, 2035 63,750 Acquired
Feb. 12, 2024 TLSIW Employee Stock Option (right to buy) Common Stock (105,000) $9.50 Feb. 11, 2034 105,000 Acquired
Aug. 30, 2023 TLSIW Employee Stock Option (right to buy) Common Stock (195,000) $6.70 Aug. 29, 2033 195,000 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

TLSIW

Chief of Clinical Operations
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2024 $501,705 · · · $125,000 · $25,014 $1,383,741

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.